Gilead continues its slide down into earnings as news of increased competition begins to creep up in all the sandboxes that it occupies. Long-term shareholders can’t seem to catch a break in the name since about a year ago. With many perceived shots on goal with products in the Hep C, Hep B, AIDS, oncology, and NASH therapeutic areas one would think that Gilead has a pipeline filled with biotech gold to keep its stock price afloat, but that hasn’t been the case.
Partners such as GlobeImmune are working hard in the Hep B space as it may be the next big thing after Hep C to be solved from a patient treatment perspective.
